Yes. 30.6% is about twice your moderate 15% single-name guideline and well above your 4–8% core-weight range; NVDA also drives 46.4% of your portfolio’s variance. The October 21 research rates it Overweight, but favors measured exposure because near-term technicals are weak and demand durability remains uncertain.
My view: trim gradually toward the 15% guideline rather than add, particularly with the position up 133.7% from your average cost. NVDA earnings are listed for November 18, but the date isn’t confirmed. AAPL, MSFT, and AMZN are also above the 15% guideline, so concentration is broader than NVDA alone.